35^th Annual European Pharma Congress

Dr. Bimal Roy Krishna is currently Professor and Director of Pharmacology at the College of Osteopathic Medicine, Touro University in Nevada. He obtained a Bachelor of Science (First Class Honors) in Pharmacology and Physiology and a Doctor of Philosophy, Medicine (OB/GYN/Pharmacology) from Monash University in Australia. Dr. Krishna also teaches for the Step 1 and COMLEX reviews for Kaplan Medical throughout the United States and in UAE, Europe, Saudi Arabia, India, Mexico and the Caribbean. He has been teaching online for Kaplan University for over 7 years. He has contributed to numerous publications and is a member of a number of organizations including Fellow-American College of Clinical Pharmacology.

His research background is in maternal and neonatal pharmacology specifically looking at materno-fetal transfer utilizing the perfused human placental and cultured syncytiotrophoblast model. Complementary and Alternative medicine is another area of interest.

The author received an honorable PhD in mathematics and majored in engineering at MIT. He attended different universities over 17 years and studied seven academic disciplines. He has spent 20,000 hours in T2D research. First, he studied six metabolic diseases and food nutrition during 2010-2013, then conducted research during 2014-2018. His approach is “math-physics and quantitative medicine” based on mathematics, physics, engineering modeling, signal processing, computer science, big data analytics, statistics, machine learning, and AI. His main focus is on preventive medicine using prediction tools. He believes that the better the prediction, the more control you have.

The author spent seven years and 18,000 hours to study, analyze and research his chronic disease conditions. Here is the comparison between 2010 and 2017: Weight: 205 / 172 lbs. Waistline: 44 / 34 inches PPG: 350 / 116 mg/dL FPG: 185 / 119 mg/dL Daily glucose: 280 / 117 mg/dL A1C: 10.0 / 6.1 % ACR: 116 / 12 mg/mmol Triglycerides: 1161 / 69 mg/dL He used mathematics, physics, engineering modeling, and computer science (big data analytics and AI) to derive the mathematical metabolism model and three prediction tools for weight, FPG, and PPG with >30 input elements. This study includes 11 categories: weight, glucose, blood pressure, lipids, food, water, exercise, sleep, stress, life pattern regularity, time, with ~500 input and output elements. He collected more than 1 million “clean” data over 7 years. He defined two new terms known as the Metabolism Index (MI) and General Health Status Unit (GHSU).

Wael k. Ali is affiliated to General Secretary of EMROpharm forum-international pharmaceutical federation (FIP) and President of Egyptian organization of pharmacy, Egypt. Wael k. Ali is a recipient of many awards and grants for his valuable contributions and discoveries in major area of subject research. His international experience includes various programs, contributions and participation in different countries for diverse fields of study.

Passion for pharmacy innovation and their need to work combined with early age are the main reasons to make new pharmacy specialties grow very fast.

Christian Schäfer is a Full-Professor at the Department of Business Administration at Baden- Württemberg Cooperative State University Mannheim (DHBW) Germany. He teaches quantitative Methods, simulation in strategic forecasting and market research in healthcare. His research interests are in the fields of quantification of uncertainty, Patient-Behaviour- Modelling, and Partial Least Squares Structural Equation Modeling (PLS-SEM). Christian also runs special forecast-simulation and market research projects for the Pharmaceutical Industry. Prior to taking this role in 2015, Christian covered different Management and Director positions in Marketing, Competitive Intelligence, Strategic Forecasting and PM- Strategy within two International Pharmaceutical Company for 8 years.

His research interests are in the fields of quantification of uncertainty, Patient-Behaviour- Modelling, and Partial Least Squares Structural Equation Modeling (PLS-SEM). Christian also runs special forecast-simulation and market research projects for the Pharmaceutical Industry.

Prof. Dr. Gholamhossein Sodeifian (1971) graduated in chemical engineering (M.S) from University of Tehran, in 1997 and received his doctorate (Ph.D), in polymer engineering from Tarbiat Modares University, Tehran, in 2002. Prof. Sodeifian is currently academic member of Chemical Engineering Department of University of Kashan. His research group focused on extraction of essential and seed oils, solubility measurement of solid medicines, and micro- and nanoparticle formation of pharmaceutical materials in supercritical carbon dioxide (SCCO2) via various methods. He has also developed, for the first time in the world, a new and efficient technique for nanoparticle formation, i.e., ultrasonic assisted rapid expansion of supercritical solution into a liquid solvent (US-RESOLV). He has published more than 83 ISI scientific papers and several books. Furthermore, he has developed Sodeifian’s model for drugs solubility. Prof. Sodeifian has been assigned and included in the worlds’ top 2% of scientists list in 2021 and 2022.

His research group focused on extraction of essential and seed oils, solubility measurement of solid medicines, and micro- and nanoparticle formation of pharmaceutical materials in supercritical carbon dioxide (SCCO2) via various methods. He has also developed, for the first time in the world, a new and efficient technique for nanoparticle formation, i.e., ultrasonic assisted rapid expansion of supercritical solution into a liquid solvent (US-RESOLV).

Professor Jun O. Liu received his B.S. degree in Chemistry from Nanjing University. He went to the US through the Chemistry Graduate Program, obtaining his MS in organic chemistry from the Ohio State University and his PhD in biochemistry from MIT. He did his postdoc at Harvard University and served as a research associate at the NIH. He served as an assistant and associate professor of chemistry and biology at MIT Center for Cancer Research before moving to his current position as a professor of pharmacology and oncology at Johns Hopkins School of Medicine. His main research interest lies in the interface between chemistry, biology and medicine. In particular, his group has been focusing on the use of natural products and existing drugs as molecular probes of various cellular processes and as novel drug leads.

Our primary research interest lies at the interface between chemistry, biology and medicine. We employ high-throughput screening to identify modulators of various cellular processes and pathways that have been implicated in human diseases from cancer to autoimmune diseases. Once biologically active compounds are identified, they will serve as both probes of the biological processes of interest and leads for the development of new drugs for treating human diseases. Among the biological processes of interest are cancer cell growth and mestastasis, apoptosis, angiogenesis, calcium-dependent signaling pathways, eukaryotic transcription and translation. Some of the ongoing projects are highlighted herein.

Dr. Emmanuel O. Akala received his B. Pharm. and M.Sc.(Pharmaceutics) from The University of Ife (now OAU) Nigeria and Ph.D. (Pharmaceutics) from The University of Manchester, England. He was a DAAD Research Scientist in Biopharmaceutics and Pharmaceutical Technology at The University of Munster, Germany, NIH-Fogarty International Fellow in Pharmaceutics and Bioengineering at The University of Utah (USA). He is a registered and immunization Pharmacist in Utah, Maryland and Washington DC.

Dr. Akala’s research interest is in novel and conventional drug products’ design and development. Current research efforts focus on Nanotechnological Platforms for the Delivery of Bioactive (Drugs) and Diagnostic Agents.

Dr Irina Ermolina is a senior lecturer in Pharmaceuticals in the School of Pharmacy, De Montfort University. She gained her PhD degree in Molecular Physics in Institute of Biochemistry and Biophysics, Russian Academy of Sciences, Kazan, Russia. Prior to joining the DMU as an academic staff, Dr Ermolina was employed as Postdoctoral Research Fellow at Glasgow University and Southampton University. Previously she worked as a senior researcher in Institute of Biochemistry and Biophysics, Kazan, Russian Academy of Sciences. Dr Ermolina now specializes in characterization of physical properties of pharmaceutical solids and powders studied by different analytical techniques; development and characterization of hydrogels as drug delivery systems; dielectric properties biological systems (proteins, DNA, cells, disaccharides); stability characterization of freeze-dried pharmaceuticals; the dynamic structure of proteins in solutions and membrane films.

Freeze-drying Pharmaceuticals Dielectric spectroscopy Thermoanalytical methods Terahertz spectroscopy Characterization of hydrogels.

Dr. Alkhateeb is the Director of Assessment & Accreditation and Associate Professor of Pharmacy at Texas A&M Health Science Center Irma Lerma Rangel College of Pharmacy. Dr. Alkhateeb has been fortunate to hold a variety of leadership positions throughout his career, including serving as the Founder and Director of the Executive MBA with a concentration in Pharmaceutical & Healthcare Management at University of Charleston, West Virginia. Moreover, he has been selected as a Fellow for the Commission on Accreditation of Health Care Management Education (CAHME). Further, he has published more than 50 peer reviewed articles and over 44 presentations and proceedings related to pharmaceutical care, pharmaceutical marketing, and accreditation and assessment in pharmacy and higher education. Dr. Alkhateeb has served as a field reviewer and evaluator for the following accreditation councils: HLC-NCA, CCAPP, ACPE, ACPE- CPE, and CAHME. Moreover, Dr. Alkhateeb is a member of the 14th Annual Texas A&M Assessment Conference Planning Committee (College Station, TX). Besides being a pharmacist, Dr. Alkhateeb has an MBA degree with concentration in Pharmaceutical Marketing & Management from Aspen University and a PhD in Pharmacy Administration with a concentration in Pharmaceutical Socioeconomics from University of Iowa College of Pharmacy, Iowa.

Dr. Alkhateeb research interests focus on Pharmacy Education and Practice, and Pharmaceutical Marketing. Dr. Alkhateeb has been increasingly drawn to pharmaceutical education research and he is currently investigating the development, delivery and assessment of effective educational programs in schools of Pharmacy. Further, he has published more than 40 peer reviewed articles related to his research interests.

Dr. Ramaiah Muthyala holds Ph.D (Natural Products), Ph.D. (Heterocyclic Chemistry) and MBA (International Management). He is Fellow of Royal Society of Chemistry. Among other awards, he received SC Amita award from the Indian Chemical Society. He has been editor or and coeditor of books, book chapters and has been in editorial boards of ARKIVOC, Mini-reviews in Medicinal Chemistry. For the last 12 years, Dr. Muthyala has been at the University of Minnesota where he was Associate Director, Center for Drug Design, and Associate Director (pre-clinical development) Center for Orphan Drug Research. He is also Associate Professor, Department of Experimental Clinical Pharmacology and Adjunct Professor, Department of Medicine. His research interests focused in rare diseases - the discovery and development of therapeutics for drug resistant bacterial infections, neurological diseases such as SCA1 and hemoglobinopathy such sickle cell disease. In his research, drug repositioning takes major emphasis to discovering drug leads.

The vision of our research program is to translate biological and chemical information into leads to drug-like molecules and optimize the lead small molecules to drug molecules using synthetic organic chemistry. The drug discovery will be combined with structure information obtained from ligand-protein structures, enzyme data derived from computational, modeling and biological experiments. The potential for speedy optimization of drug discovery, selective and carefully designed combinatorial small libraries along with rapid, sensitive and specific assay procedures are being explored. Natural products with desired biological activity at nanomolar range are considered as informed lead compounds for further development into drug candidates.

Professor of Pharmacy Practice and Director, Center for Advancement of Drug Research and Evaluation, College of Pharmacy, Western University of Health Sciences, Pomona, USA. Professor Moses SS Chow was awarded his Doctor of Pharmacy in 1972 from the University of California, San Francisco, USA; and he completed his residency in Clinical Pharmacy at VA Hospital, Palo Alto, USA.Currently, Professor Chow is Professor of Pharmacy Practice and Director of the Center for Advancement of Drug Research and Evaluation (CADRE), College of Pharmacy at the Western University of Health Sciences, Pomona, USA. He is also an adjunct professor at the Chinese University of Hong Kong, China.

Dr. Chow has over 30 years of experience in transitional research and clinical studies in the areas of cardiovascular pharmacotherapy and application of pharmacokinetics/pharmacogenomics. His recent research work has been devoted to the development of conventional drugs and herbal medicines (Chinese medicines). He has also established a strong net work with Asian countries, especially China where he served as Director of the Pharmacy School in Hong Kong for 8 years. As Director of the newly established Center for Drug Research and Evaluation at Western U, the focus of his research will be the development of niche pharmaceutical products via formulation optimization as well as new therapeutic approaches. This will be accomplished via collaborative efforts among members in formulation science, bio-analysis/ pharmacokinetics, pharmacology/pharmacogenetics and clinical/outcome studies.

Dr. Hechmi TOUMI graduated from the University Blaise Pascal, Researcher assistant at Wisconsin University and awarded professor at the University of Wales, UK. He is currently a professor of Muscular Skeletal Pathology, the Dean of the Faculty of Science and Technology at the Orleans University France, Vice Director Laboratory EA 4708 - I3MTO and Vice President of the Institute of Research, Treatment & Prevention of Osteoporosis. Hechmi Toumi founded Demasq, Cardiff UK Limited in February 2008 and also serves as its Chief Scientific Officer. He is the inventor of the international patent filing on the use of algorithmic analyses to identify and quantify ‘invisible’ detail in soft tissues in standard radiographs. Professor Toumi is a Member of the Editorial boards the journal Medicine & Science in Sports & Exercise and Journal of Foot and Ankle. His research focuses on Bone, Cartilage and soft tissue injuries. He has lectured worldwide on the Pathologies, Treatment and Prevention of muscular skeletal injuries.

His clinical interest is the assessment of pathoanatomical features of the Knee joint. He has developed a tertiary referral clinic for the investigation and management of knee pain with Professor John Fairclough highly qualified Consultant Orthopaedic Surgeons at the CMAT centre (Centre for Musculoskeletal Analysis and Therapy, Cardiff UK) where there is provision both diagnostic and therapeutic rehabilitation and is widely used by professional and amateur sports teams and individuals. He recently created jointly with Dr Eric Lespessailles (Rheumatologist and Professor associate at Orleans university) private referral clinic at the Regional Hospital at Orleans for the investigation and management of knee pain

2009 - present Assistant Professor in Department of Molecular Science and Technology, Ajou University, Korea 2002 - 2003 Post Doct., in Institute for Medicine and Engineering, University of Pennsylvania, USA 2001 - 2002 Post Doct., in Department of Chemistry, University of Massachusetts Lowell, USA 1998 - 2001 Ph.D., in Department of Electronic Chemistry, Tokyo Institute of Technology, Japan 1986 - 1990 B.S., in Department of Polymer Science and Engineering, Inha University, Korea 1996-1998 M.S., in Department of Polymer Science and Engineering, Inha University, Korea

Polymer Science and Engineering

Filippo Boniforti has degeed at the age of 26 years from Universita’ degli Studi di Milano School of Medicine and specialized in orthopedics surgery. He is the director of the Orthopedic Department of the Fondazione San Raffaele Giglio di Cefalu (I). He has published more than twenty papers in reputed journals and serving as an editorial board member of repute orthopedic societies.

He leads orthopaedic hospital unit, 16 beds for orthoapedic treatments. He runs surgical theatre for more than 800 procedures per year. Hip and knee joint replacement (primary and revision) are the most significant filds of interest (>300 procs/year), pediatric orthopaedics and, proteogenomics.

Twenty years of experience studying of the role of the preotic anterior hypothalamic area in the central control of host defense mechanisms; LPS effects on neurotransmitters and hypothalamic releasing hormones, LPS-fever, and endotoxic hypotension, make me well suited to be the Principal Investigator in the project with Dr. Arnold Johnson as Co-Investigator. The proposal pertains to the elucidation of the role of preoptic hypothalamic endocannbinoids in the lung response to endotoxemia. After five years of postdoctoral research associate/instructor and research assistant professor positions at St. Jude Children’s Research Hospital and the University of Tennessee, Health Science Center, respectively, I accepted a tenure track Assistant Professor position at Albany College of Pharmacy and Health Sciences in the fall of 2005. I have been successful in transitioning from a purely Research environment to one that has more balance of teaching and research. I successfully taught large lecture pathophysiology and pharmacology courses, a small neuroimmunology elective course and a graduate topics course in inflammation and prostaglandins. At the same time, I have developed my lab to the point where it is producing publishable data and is attracting both undergraduate and graduate students. I obtained an R15 AREA grant in the field of LPS fever and fellowships for students in the lab. As a result, I was promoted to Associate professor with tenure. To date, I have mentored 18 undergraduate students (both B.S. and Pharm.D. students) in my lab. Recently, one of these students, Janey James, was accepted at Mount Sinai Hospital, New York, NY, Graduate program. Three of my undergraduate students have competed for and received ACPHS Student Summer Research Awards to pursue research with me during the summers. I am also actively participating in mentoring students in the MS Pharmaceutical Sciences program with one of my graduate students successfully defending her thesis last week and accepted into the prestigious PhD program in immunology at Rutgers University. The undergraduate and graduate students in my lab have been major contributors to my research program in the last 9 years as evidenced by the publication/presentations in national and international meetings, and manuscripts under preparation/submitted (11, 12, 13, 15). In addition to these publications and presentations, students from my lab are the first author/co-author on two other manuscripts that are currently under review.

Host defense mechanisms,LPS effects on neurotransmitters

Upon completion of his doctorate in chemistry at The University of Tokyo in 1995 Dr. Yan joined the R&D group at Ibaraki Research Laboratory, Hitachi Chemical Industry Co. Ltd. where he carried out research works to develop sophisticated electronic components by utilizing functional polymers. After his research works on conductive polymers at Tokyo University of Science, Yamaguchi for 6 years, and on polymer gels and super water-repellent materials at Hokkaido University for 3 years, Dr. Yan joined the Laboratory of Organic Robotics at the University of Yamanashi in 2007 where he is an Associate Professor. Before his above career in Japan, Dr. Yan had been educated in China, i.e., in Jilin University (1978-1982) for Bachelor of Science on polymer chemistry and in Henan Institute of Chemistry (1984-1987) for Master of Science on inorganic chemistry. Dr. Yan who is a full professor of Zhengzhou University since 2011, has published 8 books, 59 original papers, and 31patents. Currently, Dr. Yan is also an Editorial Board Member, Journal of Bioequivalence & Bioavailability(OMICS Publishing Group, USA), and an Editorial Advisory Board Member, Recent Patents on Materials Science (Bentham Science Publishers, Ltd., USA).

Polymer Chemistry